Recursion is a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation.

View our most recent corporate materials.

Recent News
Nov 8, 2022

Initiated our Phase 2 clinical trial for the potential treatment of familial adenomatous polyposis (FAP) Initiated our Phase 1 clinical trial for the potential treatment of Clostridium difficile...

Nov 2, 2022

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:...

Oct 25, 2022

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced today that it has entered into a stock purchase agreement for the...

Stock Info
NASDAQRXRX